Римские критерии 2016 синдром раздраженного кишечника

1. Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology, 2016, 150: 1393–1407.

2. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med, 2017, 6(11). pii: E99.

3. Самсонов А.А., Андреев Д.Н., Дичева Д.Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека, 2014, 18: 7-14

4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther, 2014, 40(9): 1023-34.

5. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol, 2014, 6: 71-80.

6. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol, 2012, 10: 712–721.

7. Маев И.В., Дичева Д.Т., Андреев Д.Н., Сенина Ю.С. Синдром раздраженного кишечника в практике гастроэнтеролога. В сб.: Актуальные вопросы ведомственной медицины. М., 2012: 83–8

8. Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008, 103: 1229–1239.

9. Halder SL, Locke GR 3rd, Schleck CD et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology, 2007, 133: 799–807.

10. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology, 1991, 100: 998.

11. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology, 2016, 150(6): 1257-61.

12. Маев И. В., Черемушкин С.В., Кучерявый Ю.А. Синдром раздраженного кишечника. Римские критерии IV. О роли висцеральной гиперчувствительности и способах ее коррекции. Методическое пособие. М., 2016

13. Андреев Д.Н., Заборовский А.В., Трухманов А.С. и др. Эволюция представлений о функциональных заболеваниях желудочно-кишечного тракта в свете Римских критериев IV пересмотра (2016 г.). РЖГГК, 2017, 1: 4-11

14. Spiegel BM, Bolus R, Agarwal N et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther, 2010, 32: 1275–1291.

15. Palsson O, Heymen S, Whitehead WE. Abdominal pain versus abdominal discomfort: implications for diagnostic assessment of irritable bowel syndrome (IBS). United Eur Gastroenterol J, 2014, 2: P405.

16. Begtrup LM, Engsbro AL, Kjeldsen J et al.A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol, 2013, 11: 956–962.

17. Андреев Д.Н., Самсонов А.А., Черемушкин С.В. Синдром раздраженного кишечника: критерии диагностики и подходы к терапии. Фарматека, 2014, 14: 6-11

18. Руководство по внутренней медицине. Под ред.: Г.П. Арутюнова, А.И. Мартынова, А.А. Спасского. Москва, 2015

19. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Функциональная диспепсия: эпидемиология, классификация, этиопатогенез, диагностика и лечение: научное досье. М.: СТ-Принт, 2015

20. Маев И.В., Дичева Д.Т., Щегланова М.П. и др. Функциональная диспепсия в свете Римских критериев IV пересмотра (2016 г.). Гастроэнтерология. Приложение к журналу Consilium Medicum, 2016, 2: 5-10

21. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol, 2010, 8: 401-9.

22. Riegler G, Esposito I. Bristol scale stool form.A still valid help in medical practice and clinical research. Tech Coloproctol, 2001, 5(3): 163-4.

23. Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther, 2012, 35: 350–359.

24. Vandvik PO, Wilhelmsen I, Ihlebaek C et al. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical impli cations. Aliment Pharmacol Ther, 2004, 20: 1195–1203.

25. Whitehead WE, Palsson OS, Levy RR et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol, 2007, 102: 2767–2776.

26. Ford AC, BercikP, Morgan DG et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology, 2013, 145: 1262–1270.

27. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA, 2008, 300: 1793–1805.

28. Menees ST, Kurlander J, Goel A et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology, 2014, 146(Suppl): S194.

29. Waugh N, Cummins E, Royle P et al. Faecal cal-protectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess, 2013, 17: 1–211.

30. Ghoshal UC, Srivastava D, Verma A et al. Tropical sprue in 2014: the new face of an old disease. Curr Gastroenterol Rep, 2014, 16: 391.

31. Ющук Н.Д., Андреев Д.Н., Кучерявый Ю.А. Острая диарея у взрослых: актуальность проблемы и новые возможности терапии. Инфекционные болезни: новости, мнения, обучение, 2017, 4(21): 99-107

32. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Черёмушкин С.В. Эволюция представлений о микроскопическом колите. Терапевтический архив, 2015, 87(4): 69-76

33. Slattery SA, Niaz O, Azia Q et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther, 2015, 42: 3–11.

34. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Синдром раздраженного кишечника. Римские критерии IV. Consilium Medicum, 2016, 8: 79-85

35. Андреев Д.Н., Дичева Д.Т. Современные немедикаментозные и фармакотерапевтические подходы к лечению синдрома раздраженного кишечника. Гастроэнтерология. Приложение к журналу Consilium Medicum, 2014, 2: 47-52

36. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med., 1995, 122: 107.

37. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med, 1999, 107: 41–50.

38. Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology, 1988, 95: 701–708.

39. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol, 2011, 106: 915–922.

40. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol, 2014, 109(Suppl 1): 2–27.

41. Hirshkowitz M, Whiton K, Albert SM et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health, 2015 Mar, 1(1): 40-43.

42. Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebocontrolled trial. Am J Gastroenterol, 2011, 106: 508–514.

43. Vazquez-Roque MI, Camilleri M, Smyrk T et al.Acontrolled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology, 2013, 144: 903–911.

44. Казюлин А.Н., Дичева Д.Т., Русс И.С., Андреев Д.Н., Парцваниа-Виноградова Е.В. Диетотерапия со сниженным содержанием ферментируемых олигосахаридов, дисахаридов, моносахаридов и полиолов (fodmap) при синдроме раздраженного кишечника. Consilium Medicum, 2016, 18(8): 75-78

45. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am. J. Gastroenterol., 2013, 108: 707.

46. Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y), 2012, 8(11): 739-45.

47. Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol, 2014, 11(4): 256-66.

48. Staudacher HM, Lomer MC, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr, 2012, 142(8): 1510-8.

49. Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol, 2010 Aug, 25(8): 1366-73.

50. Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 2014, 146: 67.

51. Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск ХVIII. М.: Видокс, 2017

52. Poynard T, Regimbeau C, Benhamou Y. Metaanalysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2001 Mar, 15(3): 355-61.

53. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex, 2012 Apr-Jun, 77(2): 82-90.

54. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic re view and meta-analysis. BMJ, 2008 Nov 13, 337: a2313.

55. Маев И.В., Самсонов А.А., Андреев Д.Н. Современный алгоритм ведения пациентов с синдромом хронического запора с позиций внедрения новых фармакологических препаратов. Фарматека, 2012, 13: 37-43

56. Кучерявый Ю.А., Андреев Д.Н., Черемушкин С.В. Хронический запор: актуальность, проблемы и современные возможности лечения. Consilium Medicum, 2017, 19(8): 116-120

57. Маев И., Дичева Д., Андреев Д. Новые возможности лечения хронического запора. Врач, 2012, 3: 45-8

58. Lavo B, Stenstam M, Nielsen AL et al. Loperamide in treatment of irritable bowel syndrome— a double-blind placebo controlled study. Scand J Gastroenterol Suppl, 1987, 130: 77–80.

59. Laterza L, Ianiro G, Scoleri I et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother, 2015 Mar, 16(4): 607-15.

60. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo), 2014 Sep, 67(9): 667-70.

61. Pozuelo M, Panda S, Santiago A et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep, 2015, 5: 12693.

62. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J. Gastroenterol, 2014, 20(10): 2456–69.

63. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther, 2017 Mar, 45(5): 604-616.

64. Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore), 2016 Jan, 95(4): e2534.

65. Schoenfeld P, Pimentel M, Chang L et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther, 2014 May, 39(10): 1161-8.

66. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос. журн. гастроэнтерол. гепатол. колопроктол., 2017, 27(5): 76-93

67. Sebastián Domingo JJ. Review of the role of pro-biotics in gastrointestinal diseases in adults. Gastroenterol Hepatol, 2017, 40(6): 417-429.

68. Zhang Y, Li L, Guo C et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol, 2016, 16(1): 62.

Источник

https://doi.org/10.22416/1382-4376-2016-26-5-99-103

Аннотация
Об авторах
Список литературы

Аннотация

Цель лекции. Проанализировать изменения, внесенные в Римские критерии синдрома раздраженного кишечника (СРК) IV пересмотра по сравнению с предшествующими критериями. Основные положения. Из определения СРК изъят термин «дискомфорт», а сочетание «боли уменьшаются после акта дефекации» заменено сочетанием «боли связаны с актом дефекации»; изменена частота дней, когда возникают боли в животе, требуемая для постановки диагноза данного заболевания. По-прежнему, при постановке диагноза СРК рекомендуется ориентироваться на соответствие имеющихся у больного симптомов Римским критериям, хотя отмечается, что с клинической картиной, свойственной СРК, могут протекать и другие заболевания (целиакия, хронические воспалительные заболевания кишечника и др.). Это обусловливает необходимость лимитированного лабораторного и инструментального обследования пациентов. В схемы лечения больных включены новые лекарственные препараты (рифаксимин, любипростон, линаклотид и др.). Заключение. Римские критерии СРК IV пересмотра представляют собой определенный шаг вперед, особенно в части диагностики и лечения рассматриваемого заболевания.

Список литературы

1. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2014; 24(2):92-101

2. Ивашкин В.Т., Алексеенко С.А., Колесова Т.А. и др. Резолюция Экспертного совета, посвященного проблемам диагностики и лечения функциональных заболеваний желудочно-кишечного тракта. Рос журн гастроэнтерол гепатол колопроктол 2016; 26(4):129-30

3. Lacy B.E., Mearin F., Lin Chang, et al. Bowel disorders. Gastroenterology 2016; 150(6):1393-407.

4. Layer P., Andresen V., Pehl C., et al. Guideline irritable bowel syndrome: definition, pathophysiology, diagnosis and therapy. Joint Guideline of the German Society for Digestive and Metaboloc Diseases (DGVS) and the German Society for Neurogastroenterology and Motility (DGNM). Z Gastroenterol 2011; 49:237-9.

5. Longstreth G.F., Thompson W.G., Chey W.D. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.

6. Mearin F. Lower gastrointestinal bowel disorders // AGA Institute Rome Foundation lectureship: the launching of Rome IV: what’s new and why? Digestive Disease Week, San Diego, 2016. Oral presentation.

7. Ruepert L., Quartero A.J., de Wit N.J., et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane Collaboration. The Cochrane Library 2013, Issue 3.

Для цитирования:

Шептулин А.А., Визе-Хрипунова М.А. Римские критерии синдрома раздраженного кишечника IV пересмотра: есть ли принципиальные изменения? Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(5):99-103.
https://doi.org/10.22416/1382-4376-2016-26-5-99-103

For citation:

Sheptulin A.A., Vize-Khripunova M.A. Review of Rome-IV criteria for the irritable bowel syndrome: are there any basic changes? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(5):99-103.
(In Russ.) https://doi.org/10.22416/1382-4376-2016-26-5-99-103

Источник

Архив журнала
/
2008
/
№10

Синдром раздраженного кишечника: путь к Римским критериям III

Румянцев В.Г.

В статье представлена хронология развития представлений о функциональных расстройствах кишечника и наиболее часто встречающейся в клинической практике форме заболевания – синдроме раздраженного кишечника (СРК). Приведены изменения, внесенные международными экспертами Римской организации, в определение болезни, классификацию, рекомендации по диагностике и лечению СРК, основанные на принципах доказательной медицины.

Литература

Atkinson W, Sheldon TA, Shaath N, et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. Gut 2004;53:1459–64.

Barbara G, Stanghellini V, DeGiorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126:693–702.

Bayless TM. Inflammatory bowel disease and irritable bowel syndrome. Med Clin N Am 1990;49:21–28.

Camilleri M, Atanasova E, Carison PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123:425–32.

Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122:1778–83.

Chang L, Berman S, Mayer EA, et al. Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol 2003;98:1354–61.

Chaudhary NA, Truelove SC. The irritable colon syndrome. Q J Med 1962;31:307–22.

Christensen J. Heraclides or the physician. Gastroenterol Int 1990;3:45–48.

Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79–86.

Cumming W. Electro-galvanism in a peculiar affliction on the mucous membrane of the bowels. London Med Gazette 1849;NS9:969–73.

Dalton CB, Drossman DA, Hathaway MD, et al. Perceptions of physicians and patients with organic and functional gastroenterological diagnoses. J Clin Gastroenterol Hepatol 2004; 2:121–26.

Delgado-Aros S, Camilleri M. Visceral hypersensitivity 2. J Clin Gastroenterol 2005;39: 194–203.

Drossman DA. Psychosocial and psychophysiologic mechanisms in GI illness. In: Kirsner J.B.,ed. The growth of gastroenterologic knowledge in the 20th century. Philadelphia: Lea & Febiger 1993:41–432.

Drossman DA. Presedential address: gastrointestinal illness and biopsychosocial model. Psychosom Med 1998;60:258–67.

Drossman DA. Challenges in the physician-patient relationship: feeling “drained”. Gastroenterology 2001;121:1037–38.

Drossman DA. Functional GI disorders: what’s in a name? Gastroenterology 2005;128:1771–72.

Drossman DA. Brain imaging and its implications for studying centrally targeted treatments in IBS: a primer for gastroenterologists. Gut 2005;54:569–73.

Drossman DA, Funch-Jensen P, Janssens J, et al. Identification of subgroups of functional bowel disorders. Gastroenterol Int 1990;3:159–72.

Drossman DA, Richter JE, Talley NJ, et al. Functional gastrointestinal disorders. Boston: Little, Brown 1994.

Drossman DA, Corazziari E, Talley NJ, et al. Rome II: a multinational consensus document on functional gastrointestinal disorders 1999.

Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional disorders? Am J Gastroenterology 2000;95:974–80.

Drossman DA, Camilleri M, mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108–31.

Drossman DA, Ringel Y, Vogt B, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe IBS. Gastroenterology 2003;124:754–61.

Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome: defining an altemator. Gastroenterology 2005;128:580–89.

Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infections IBS. Gastroenterology 2003;125:1651–59.

Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349–57.

Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196:129–36.

Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry 1980; 137:535–44.

Evans B, Clark W, Moore D, et al. Tegaserod foe the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; 1:CD003960.

Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome 2. J Clin Gastroenterol 2005; 39:184–93.

Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91–93.

Gorard DA, Libby GW, Farthing MJG. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40:86–95.

Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005;100:1174–84.

Gwee K-A. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? Neurogastroenterol Motil 2005; 17:317–24.

Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523–26.

Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997;11:553–59.

Hale-White W. Colitis. Lancet 1895;1:537.

Heaton KW, Ghosh S, Braddon FEM. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991;32:73–79.

Heitkemper M, Carter E, Ameen V, et al. Women with irritable bowel syndrome: differences in patients’ and physicians’ perceptions. Gastroenterol Nurs 2002;25:192–200.

Hobday DI, Aziz Q, Thacker N, et al. A study of the cortical processing of anj-rectal sensation using functional MRI. Brain 2001;124:361–68.

Holtmann G, Siffert W, Haag S, et al. G-protein beta3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971–79.

Isgar B, Harman M, Kaye MD, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983;24:190–92.

Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systemic review of randomized, controlled trials. Ann Intern Med 2000;133:136–37.

Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004;53:829–37.

Kruis W, Thieme CH, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1–7.

Lancaster-Smith MJ, Prout BJ, Pinto T, et al. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982;66:33–41.

Levy RL, Whitehead WE, Von Korff MR, et al. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95:451–56.

Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122–29.

Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852–58.

Locke GR, Pemberton JH, Phillips SF. AGA technical review on constipation. Gastroenterology 2000;119:1766–78.

Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003;98:600–07.

Longstreth GF. Definition and classification of IBS: current consensus and controversies. Gastroenterol Clin North Am 2005;34:173–87.

Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol 2005; 3:397–400.

Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653–54.

Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000;47:861–69.

Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271–93.

Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol 2003;15:165–72.

Mertz H, Fass R, Kodner A, et al. Effect of amitryptiline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160–65.

Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842–48.

Morgan V, Pickens D, Shyr Y. Anxiety is associated with increased anterior cingulated but not thalamic activation during rectal pain in IBS and controls. Gastroenterology 2001;120(Suppl. 1):3850.

Naliboff BD, Derbyshire SWG, Munakata J, et al. Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid stimulation. Psychosom Med 2001; 63:365–75.

Niaz SK, Sandrasegaran K, Renny FH, et al. Postinfective diarrhea and bile acid malabsorption. J R Coll Psysicians Lond 1997;31:53–56.

O’Donnell LJD, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. Br Med J 1990;300:439–40.

O’Leary C, Wieneke P, Buckley S, et al. Celiac disease and irritable bowel-type symptoms. Am J Gastroenterol 2002;6:1463–67.

Onghena P, Houdenhove BV. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992;49:205–19.

Parker TJ, Woolner JT, Prevost AT, et al. Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001;13:219–25.

Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592–22.

Powell R. On certain painful afflictions of the intestinal canal. Med Trans Royal Coll Phys 1818;6:106–17.

Quigley EMM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterol 2001;120:263–86.

Quigley EMM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chinese J Dig Dis 2005;6:122–32.

Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients; description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998; 10:415–21.

Ragnarsson G, Bodemar G. Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol 1999;34:993–1000.

Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005;100:936–71.

Read M, Read NW, Barber DC, et al. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci 1982;27:807–14.

Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001;76:511–27.

Ringel Y, Drossman DA, Leserman J, et al. Association of anterior cingulated cortex (ACC) activation with psychosocial distress and pain reports. Gastroenterology 2003;124(4):A-97.

Saito YA, Schoenfeld P, Locke GRI. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol 2002;—97:1910-1915.

Skoog SM, Bharucha AE. Dietary fructose and gastrointestinal symptoms: a review. Am J Gastroenterol 2004;99:2046–50.

Snook J, Shepherd AH. Bran supplementation in the treatment of the irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:511–14.

Sperber AD, Carmel S, Atzmon Y, et al. Use of the functional bowel disorder severity index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000;95:995–98.

Spiegel BM, Derosa VP, Gralnek IM, et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004;126: 1721–32.

Spiller RC. Post infectious irritable bowel syndrome. Gastroenterology 2003;124:1662–71.

Stam R, Ekkelenkamp K, Frankhuijnzeel AW, et al. Long-lasting changes in central nervous system responsivity to colonic distension after stress in rats. Gastroenterology 2002; 123:1216–25.

Su X, Gebhart GF. Effects of tricyclic antidepressants on mechanosensitivity pelvic nerve afferent fibers innervating the rat colon. Pain 1998;76:105–14.

Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995;333:1–4.

Tillisch K, Labus JS, Naliboff BD, et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005;100:896–904.

Thompson WG. Proctalgia fugax. Dig Dis Sci 1981;26:1121–24.

Thompson WG. Gut reactions. New York; Plenum, 1989.

Thompson WG, Dotevall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989;2:92–95.

Thompson WG, Creed FN, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992;5:75–91.

Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. In: Drossman D.A., Corazziari E., Talley N.J. et al. (eds). The functional gastrointestinal disorders. 2nd ed. Washington: Degnon, 2000.

Thompson WG, Heaton KW. Irritable bowel syndrome. 2nd ed. Abbington, Oxford: Health Press, 2003.

Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gut 1999;45:43–47.

Verne GN, Himes NC, Robinson ME, et al. Central representation of cutaneous and visceral pain in irritable bowel syndrome. Gastroenterology 2001;120(Suppl. 1):A713.

Walters B, Vanner S. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100: 1566–70.

Whitehead WE, Crowell MD, Bosmajian L, et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990; 98:336–40.

Whitehead WE, Paulsson O, Jones KR. Systematic review of the comorbidity or irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140–56.

Whitehead WE, Bassotti G, Palsson O, et al. Factor analysis of bowel symptoms in US and Italian populations. Dig Liver Dis 2003; 35:774–83.

Wilson A, Longstreth G, Knight K, et al. Quality of life in managed care patients with irritable bowel syndrome. Manage Care Interface 2004;17:24–28.

Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. Gut 2004;53:1452–58.

Mueller-Leissner S, Tytgat GN, Paulo LG, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006;23:1741–48.

Tytgat GN. Hyoscine butylbromide. A review of its use in treatment of abdominal cramping and pain. Drugs 2007;67(9):1343–57.

Ishii M, Kurachi Y. Muscarinic acetylcholine receptors. Curr Pharmaceut Des 2006; 12(28):3573–81.

Источник